
Humaan VHL antilichaam
Kwaliteit
ISO Gecertificeerd
Levering
24-48 uur
Technische Specificaties
Von Hippel-Lindau disease (VHL) is a dominant inherited syndrome characterized by the predisposition todevelop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas andhemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in theVHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-typeallele. VHL has two domains: a roughly 100-residue NH2-terminal domain rich in beta sheet (beta-domain) anda smaller alpha-helical domain (alpha-domain), held together by two linkers and a polar interface. VHL proteinis also involved in the degradation of hypoxia-inducible factor (HIF) .
Von Hippel-Lindau tumor suppressor isoform 1, Von Hippel-Lindau tumor suppressor isoform 1, HRCA1, RCA1, VHL1, Von Hippel-Lindau tumor suppressor isoform 1 pVHL, G7 protein, Elongin bindingprotein, HRCA 1, RCA 1, VHL, VHL 1, VHLH, Von Hippel Lindau disease tumor suppressor, vonHippel Lindau syndrome, von Hippel Lindau tumor suppressor, AVH0616
• Mouse
Human
Human
Recombinant human VHL (1-154aa) purified from E. coli
• Monoclonal
• IgG2b κ
AT82B10
Unconjugated
ELISA, WB, ICC/IF
By protein-A affinity chromatography
1 mg/mL (determined by BCA assay)
VHL, ATGA0542-10 µg, ATGA0542-20 µg, ATGA0542-50 µg, ATGA0542-100 µg, ATGA0542-250 µg, ATGA0542-500 µg, ATGA0542-1 mg, ATGA0542-10, ATGA0542-20, ATGA0542-50, ATGA0542-100, ATGA0542-250, ATGA0542-500, ATGA0542-1
Latif F., et al. (1993) Science. 260 (5112) : 1317-20.; ; Duan DR., et al. (1995) PNAS. 92 (14) : 6459-63.; ; Maxwell PH., et al. (1999) Nature. 399 (6733) : 271-5.;
Can be stored at 2°C to 8°C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.
Liquid in. Phosphate-Buffered Saline (pH 7.4) with 0.02% Sodium Azide, 10% glycerol
The antibody has been tested by ELISA, Western blot and ICC/IF analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results.
Cancer
NP_000542
P40337
The cell lysates (40ug) were resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human VHL antibody (1:1000) . Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.; ; Lane 1.: HepG2 cell lysate; ; Lane 2.: HeLa cell lysate; ; Lane 3.: Raji cell lysate; ; Lane 4.: Jurkat cell lysate; ; Lane 5.: A549 cell lysate; ; Lane 6.: MCF7 cell lysate; ; Lane 7.: PC3 cell lysate;
ICC/IF analysis of VHL in Hep3B cells. The cell was stained with ATGA0542 (1:100) . The secondary antibody (green) was used Alexa Fluor 488. DAPI was stained the cell nucleus (blue) .
Beschrijving
Von Hippel-Lindau disease (VHL) is a dominant inherited syndrome characterized by the predisposition todevelop various kinds of benign and malignant tumors, inc
Specificaties
Recent bekeken producten

Human Mast Cells - Dermis
ABC-TC105W
1 Vial

CYP1A2 Inhibitor Screening Assay
MA-0389
200 Well

Culture Medium for Immortalized Human Parathyroid Cells
AFG-ELL-2645-01
100 mL

Immortalized Human Parathyroid Cells
AFG-ELL-2055
> 1x 10^6 Cells / Vial

1,4- Dioxane Pure
1041330 500
500 mL

EPS8 Antibody (N-term) [APR32555G]
APR32555G-01
50 µL

Prestained Protein Ladder (25-300 kDa)
CRG1114
250 µL

Rat IgG Lyophilized
B2013903
25 mg
Recent gezochte producten

Hsa-miR-1258 mimic
HY-R00162-01
5 nmol

Hsa-miR-4258 mimic
HY-R00937-01
5 nmol

hsa-miR-1258 miRNA Mimic
MBS8298831-01
5 nmol

hsa-miR-4258 miRNA Mimic
MBS8299087-01
5 nmol

hsa-miR-1258 miRNA Agomir
MBS8311479-01
5 nmol

Hsa-miR-1258 miRNA Mimic
CMH0784-01
5 nmol

Hsa-miR-4258 miRNA Mimic
CMH1040-01
5 nmol

Hsa-miR-4258 miRNA Agomir
CMJ1040-01
5 nmol
